Seattle, WANCT06053580Now EnrollingIRB Ready

Pulmonary Arterial Hypertension Clinical Trial in Seattle, WA

Access cutting-edge pulmonary arterial hypertension treatment through this phase 2 clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.

Sponsored by University of Washington

Quick Self-Assessment

See if you qualify for this Seattle location

Preparing your pre-screening questions…

Expert Care in Seattle

Access pulmonary arterial hypertension specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pulmonary arterial hypertension treatment provided free

Apply for This Seattle Location

Check if you qualify for this pulmonary arterial hypertension clinical trial in Seattle, WA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Seattle

    Convenient for WA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Seattle site if eligible
  4. 4Begin participation

About This Pulmonary Arterial Hypertension Study in Seattle

This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.

Sponsor: University of Washington

Who Can Participate

Inclusion Criteria

Male or female, age 18 to 80
WHO Group 1 Pulmonary Arterial Hypertension
NYHA Functional Class II, III, or IV at screening (Appendix 2 for Functional Class Decision Aid)
Right heart catheterization within five years demonstrating a mean pulmonary arterial pressure of ≥25 mmHg, occlusion pressure of ≤15 mmHg, and resistance ≥ 3 wood units
Participants with a right heart catheterization within five years demonstrating a mean pulmonary arterial pressure of ≥ 25 mmHg and occlusion pressure of 15 - 20 mmHg will be considered for inclusion if the pulmonary vascular resistance ≥ 9 wood units and they are being treated with pulmonary arterial hypertension specific therapy
Able to walk with/without a walking aid for a distance of at least 50 meters

Exclusion Criteria

Pregnant or lactating
Non-group 1 pulmonary hypertension or veno-occlusive disease
History of interstitial lung disease, unless subject has collagen vascular disease and has pulmonary function testing conducted within 12 months demonstrating a total lung capacity or vital capacity of ≥ 60 %
Has received or will receive an investigational drug, device, or study within 30 days or during the course of study
ACE-inhibitor, ARB or ARNI use within 30 days of randomization.
Left sided myocardial disease as evidenced by left ventricular ejection fraction \< 40%
Any other clinically significant illness or abnormal laboratory values (measured during the Screening period) that, in the opinion of the Investigator, might put the subject at risk of harm during the study or might adversely affect the interpretation of the study data
Anticipated survival less than 1 year due to concomitant disease
Allergy or angioedema with ACE-inhibitor use
Potassium \>5mEq/L or sCr \>2mg/dL at screening
SBP \<90mmHg at screening

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Seattle?

Yes, this clinical trial (NCT06053580) has an active research site in Seattle, WA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pulmonary Arterial Hypertension Treatment Options in Seattle, WA

If you're searching for pulmonary arterial hypertension treatment options in Seattle, WA, this clinical trial (NCT06053580) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Seattle research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced pulmonary arterial hypertension specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pulmonary arterial hypertension clinical trials near you to find additional studies recruiting in your area.

More Hypertension Trials in Seattle, WA

See all hypertension clinical trials recruiting in Seattle — not just this study.

Browse Hypertension Trials in Seattle →

Browse More Trials by Condition

Hypertension TrialsPulmonary Embolism TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Seattle?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Seattle, WA